Why TrumpRx’s Real Test Is Pharmacy Access, Not Price
TrumpRx now lists 800+ drugs, but AMCP’s Adam Colborn says a discounted price means nothing if the local pharmacy won’t
Read MoreDaily intelligence on pharma market access — formulary decisions, reimbursement and payer policy, hospital pharmacy procurement, and the regulatory and pricing dynamics shaping patient access to medicines.
TrumpRx now lists 800+ drugs, but AMCP’s Adam Colborn says a discounted price means nothing if the local pharmacy won’t
Read MoreFTC settlements with Express Scripts and CVS Caremark are forcing structural transparency into PBM operations — here’s what changes and
Read MoreEmployer contracts with the Big Three PBMs dropped nearly 10 points in a single year — and over half are
Read MoreThree PBM-owned pharmacies control two-thirds of specialty drug dispensing revenue — here’s the full landscape access teams need to navigate.
Read MoreVizient and Premier alone represent over 60% of US hospital beds — here’s the full GPO landscape shaping formulary and
Read MoreThree companies process 80% of all US prescription claims — here’s the full PBM and market access landscape hospital pharmacy
Read More